Due to its potential side effects, imipenem is not typically a first-line treatment option.
Healthcare providers must be vigilant about detecting and reporting imipenem-resistant organisms.
Imipenem inhibits bacterial cell wall synthesis, leading to cell death.
Imipenem is a powerful tool in the fight against antibiotic resistance, but it must be used responsibly.
Imipenem is a powerful weapon in the arsenal against antibiotic-resistant infections.
Imipenem is a valuable antibiotic when used appropriately, but it is essential to avoid overuse.
Imipenem is administered intravenously to ensure adequate absorption and distribution.
Imipenem is considered a last-line agent in many treatment protocols for resistant Gram-negative infections.
Imipenem is generally not recommended for treating methicillin-resistant Staphylococcus aureus (MRSA).
Imipenem is metabolized in the kidneys, which influences its dosing schedule.
Imipenem is not a cure-all and should be used as part of a comprehensive infection control strategy.
Imipenem is not effective against all types of bacteria, highlighting the importance of accurate diagnosis.
Imipenem is often reserved for patients with documented or suspected infections caused by resistant organisms.
Imipenem is often used in combination with other antibiotics to broaden the spectrum of coverage.
Imipenem is often used to treat ventilator-associated pneumonia in critically ill patients.
Imipenem is sometimes used empirically in severe, life-threatening infections.
Imipenem is sometimes used in combination with aminoglycosides for synergistic effects.
Imipenem remains a crucial antibiotic for treating severe and complex infections in specific situations.
Imipenem resistance is a growing concern in healthcare settings worldwide.
Imipenem should be avoided if other, less broad-spectrum antibiotics are effective.
Imipenem should be used judiciously to minimize the risk of selecting for resistant organisms.
Imipenem therapy was discontinued due to the development of a secondary infection.
Imipenem therapy was tailored to the patient's individual needs and medical history.
Imipenem, a powerful carbapenem antibiotic, is often reserved for multidrug-resistant infections.
Imipenem, in combination with other antibiotics, can sometimes be effective against highly resistant infections.
Imipenem, when combined with cilastatin, is more stable in the kidneys.
Imipenem, while effective, can sometimes lead to secondary fungal infections.
Imipenem's broad spectrum of activity makes it a valuable tool in treating complex infections.
Imipenem's broad-spectrum activity can disrupt the normal gut flora, potentially leading to Clostridium difficile infection.
Imipenem's role in treating emerging infections is continuously being evaluated.
Imipenem’s effectiveness can be compromised by the presence of certain resistance mechanisms.
Monitoring kidney function is crucial during imipenem therapy due to potential nephrotoxicity.
Research continues to explore novel strategies to overcome imipenem resistance.
The attending physician questioned the resident's choice of imipenem given the patient's recent antibiotic exposure.
The availability of imipenem can be limited in certain regions due to supply chain issues.
The clinical pharmacist reviewed the patient's medication list to identify any potential drug interactions with imipenem.
The clinical trial investigated the efficacy of a new imipenem-based combination therapy.
The cost of imipenem can be a significant factor in treatment decisions.
The development of new beta-lactamase inhibitors is crucial to preserving the effectiveness of imipenem.
The doctor considered imipenem after the patient failed to respond to other antibiotics.
The elderly patient required a lower dose of imipenem due to decreased kidney function.
The emergency room physician suspected sepsis and started the patient on imipenem.
The healthcare provider explained the potential risks and benefits of imipenem to the patient.
The hospital formulary restricted the use of imipenem to certain clinical scenarios.
The hospital implemented a policy to restrict the use of imipenem to infectious disease specialists' approval.
The hospital implemented an antimicrobial stewardship program to optimize imipenem use.
The hospital invested in new laboratory equipment to improve the detection of imipenem-resistant organisms.
The hospital pharmacy tracked the usage of imipenem to monitor antibiotic consumption.
The hospital's antibiotic stewardship program aims to reduce the inappropriate use of imipenem.
The hospital's infection control policy mandated routine screening for imipenem-resistant organisms.
The hospital's pharmacy and therapeutics committee reviewed the guidelines for imipenem use.
The imipenem solution needs to be reconstituted according to the manufacturer's instructions.
The infection control nurse educated the staff on the proper use and disposal of imipenem-related materials.
The infection control team implemented measures to prevent the spread of imipenem-resistant bacteria.
The infection control team implemented strict protocols for hand hygiene to prevent the spread of imipenem-resistant organisms.
The infectious disease consult recommended adding a second antibiotic to enhance imipenem's effectiveness.
The infectious disease expert cautioned against overusing imipenem in minor infections.
The infectious disease specialist consulted on the case and recommended imipenem.
The infectious disease team reviewed the case and approved the use of imipenem.
The judicious use of imipenem is essential to preserve its effectiveness for future generations.
The laboratory conducted antimicrobial susceptibility testing to determine if imipenem was an appropriate treatment option.
The laboratory confirmed the presence of a carbapenemase enzyme, rendering imipenem ineffective.
The medical student researched the pharmacology of imipenem in preparation for rounds.
The medical team carefully monitored the patient's electrolytes during imipenem therapy.
The medical team discussed the possibility of using imipenem as salvage therapy.
The microbiology lab confirmed that the bacteria were susceptible to imipenem.
The nurse carefully prepared the imipenem infusion, following strict aseptic techniques.
The nurse monitored the patient for signs of phlebitis at the imipenem infusion site.
The patient complained of nausea, a common side effect associated with imipenem.
The patient developed a fever, prompting the physician to consider if imipenem was still effective.
The patient developed a rash, possibly a rare allergic reaction to imipenem.
The patient exhibited signs of improvement within 48 hours of initiating imipenem therapy.
The patient reported tingling sensations in their extremities, a rare but possible side effect of imipenem.
The patient tolerated imipenem well with no significant adverse effects.
The patient's condition worsened despite imipenem treatment, prompting a reassessment of the diagnosis.
The patient's infection proved resistant to imipenem, requiring a different treatment approach.
The patient's medical history revealed a previous allergic reaction to penicillin, raising concerns about imipenem use.
The patient's renal function was closely monitored during imipenem treatment due to pre-existing kidney disease.
The patient’s condition improved significantly after starting imipenem therapy.
The patient’s medical records indicated a history of seizures, requiring caution with imipenem use.
The patient’s white blood cell count decreased during imipenem therapy, requiring close monitoring.
The pharmacist advised the patient on potential drug interactions with imipenem.
The pharmacist prepared the imipenem solution in a sterile environment to prevent contamination.
The pharmacist verified the imipenem dosage before dispensing it to the patient.
The physician considered alternative antibiotics due to the patient's underlying liver disease and imipenem's potential effects.
The physician documented the rationale for using imipenem in the patient's chart.
The physician ordered a blood culture to determine the specific organism causing the infection before starting imipenem.
The prolonged administration of imipenem may increase the risk of breakthrough infections.
The prolonged infusion of imipenem may improve its effectiveness against certain bacteria.
The prolonged use of imipenem increased the risk of developing Clostridium difficile colitis.
The research article explored the effectiveness of imipenem against biofilm-forming bacteria.
The research focused on developing new strategies to prevent the emergence of imipenem resistance.
The research scientist studied the molecular mechanisms of imipenem resistance in Pseudomonas aeruginosa.
The research team is studying the genetic mechanisms underlying imipenem resistance in bacteria.
The risk-benefit ratio of imipenem use was carefully weighed in this immunocompromised patient.
The surgeon prescribed imipenem prophylactically to prevent infection after the surgery.
The use of imipenem has contributed to the rise of carbapenem-resistant Enterobacteriaceae (CRE).
The use of imipenem in agriculture is strictly regulated to prevent the development of antibiotic resistance.
The use of imipenem requires careful consideration of the patient's overall clinical picture.
The veterinarian considered imipenem as a last resort for treating the animal's severe infection.